The US medical devices industry saw a rise of 19.7% in overall deal activity during May 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 85 deals worth $8.22bn were announced in May 2019, compared to the 12-month average of 71 deals.
Venture financing was the leading category in the month in terms of volume with 64 deals which accounted for 75.3% of all deals.
In second place was M&A with 18 deals, followed by private equity with three transactions, respectively accounting for 21.2% and 3.5% of overall deal activity in the country’s medical devices industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $7.29bn, while venture financing and private equity deals totalled $876.56m and $55m, respectively.
US medical devices industry deals in May 2019: Top deals
The top five medical devices industry deals accounted for 90.7% of the overall value during May 2019.
The combined value of the top five medical devices industry deals stood at $7.46bn, against the overall value of $8.22bn recorded for the month. The top announced US medical devices industry deal tracked by GlobalData in May 2019 was 3M’s $6.73bn acquisition of Acelity.
In second place was the $465m acquisition of VertiFlex by Boston Scientific and in third place was Biomatics Capital Partners, BlueCross BlueShield Venture Partners, Camden Partners Holdings, Casdin Capital, Cowin Venture Capital, Exact Sciences, Gamma3, Section 32, Invus Group and Third Rock Ventures’ $110m venture financing of Thrive Earlier Detection.
The $97m acquisition of Soluble Systems by Misonix and Boulder Ventures, Longwood Fund Management, PBM Capital Group, Peierls Foundation and Perceptive Advisors’ venture financing of ArcherDx for $60m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.